Key facts
- Aarvik Therapeutics’s last known valuation is $51.2M (Dec 2024).
- It has raised $11.5M across 2 recorded rounds; the latest was Seed Round ($1.2M) in Nov 2024.
- Notable investors include Laurus Labs.
- Aarvik Therapeutics has filed 2 Form Ds with the SEC since 2021, most recently Dec 2024 ($1.2M sold to 5 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Aarvik Therapeutics
Funding rounds
2 roundsAbout Aarvik Therapeutics
Operator of a proprietary modular platform intended to develop site-specific antibody-drug conjugation technology. The company tool is being used to generate a pipeline of proprietary multi-functional ADCs that engage multiple epitopes/targets to result in effective treatments where previous-generation ADCs failed or were sub-optimal and develop novel molecules with an improved therapeutic index for oncology targets, enabling biotechnology companies to create transformational benefits for cancer patients.
- Sector
- Healthcare
- HQ
- Hayward, CA, United States
- Founded
- 2020
- Employees
- 11
- Website
- aarviktx.com/
- Ownership
- Privately Held (backing)
Aarvik Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aarvik Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aarvik Therapeutics in its N-PORT filings yet. We sweep new filings monthly.